David Baidal, MD
Fellowship:Beth Israel Deaconess Medical Center - Joslin Diabetes Center, Harvard Medical School.
Residency:Jackson Memorial Hospital, University of Miami.
MD:Universidad Catolica Santiago de Guayaquil.
David Baidal, M.D., is Assistant Professor of Medicine in the Division of Endocrinology, Diabetes, & Metabolism University of Miami, Miller School of Medicine. Dr. Baidal received his medical degree from Universidad Catolica Santiago de Guayaquil in Ecuador. He completed his internal medicine residency at Jackson Memorial Hospital, University of Miami and then went on to complete a clinical and research fellowship in Endocrinology, Diabetes & Metabolism at the Beth Israel Deaconess Medical Center / Joslin Diabetes Center in Boston.
He is a former member of the Clinical Islet Transplant Program at the Diabetes Research Institute, where his research primarily focused on the identification of metabolic markers predictive of islet allograft dysfunction.
Following completion of his clinical fellowship, he has now rejoined the Clinical Cell Transplant Program at the Diabetes Research Institute, where he will focus on the management of islet transplant recipients and the development of new clinical trials for islet transplantation and testing novel therapies for the treatment of new onset type 1 diabetes.
Dr. Baidal is providing medical care to patients with endocrine disorders in particular patients with type 1 diabetes.
Dr Baidal is currently working on the identification of an optimal site for clinical islet transplantation that would allow for improved engraftment, delivery of local immunosuppression, physiologic insulin delivery and drainage, and tissue retrieval for tissue assessment. He is evaluating the utilization of continuous glucose monitoring for optimization of glucose control during the peri-transplant period in recipients of islet transplants. He will also be focusing on the evaluation of the secretory responses to glucose secretatogues of islet grafts implanted on the omentum to determine differences compared to responses observed in intrahepatic islet transplant recipients. Another area he will be working on will be determining whether counter-regulatory responses triggered by hypoglycemia are restored in recipients of omental islet transplants and how they compare to intrahepatic islet allografts.